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INTRODUCTION
The overall survival rate for Wilms tumor is 90%. While this
ﬁgure speaks to the remarkable treatment advances over the past
40 years achieved through successive studies conducted by the
National Wilms Tumor Study Group (NWTSG) and the Interna-
tional Society of Pediatric Oncology (SIOP), it understates the
need for further research. Approximately 30% of patients with
pediatric renal tumors have survival rates less than 70%, including
those with relapsed favorable histology Wilms tumor (FHWT)
[1–3], anaplastic Wilms tumor (AHWT) [4], blastemal-type
Wilms tumor after pre-operative chemotherapy [5], malignant
rhabdoid tumor (MRT) [6,7], and renal cell carcinoma (RCC)
[8,9]. Moreover, the high cure rate for Wilms tumor comes at a
cost, as 25% of survivors have serious chronic health conditions
25 years from diagnosis [10].
The NWTSG and SIOP studies differ in their approach to the
timing of surgical resection. The NWTSG and its successor, the
Children’s Oncology Group (COG) Renal Tumor Committee,
advocate for immediate nephrectomy to ensure accurate histologic
diagnosis and staging. The SIOP Renal Tumor Study Group
advocates for pre-operative chemotherapy to promote tumor
shrinkage and thereby facilitate surgery. Both approaches produce
similar overall survival rates. It is important to recognize that
because pre-operative chemotherapy alters stage and histology,
prognostic factors must be considered in the context of the therapy
given. The present article describes the state of the ﬁeld as seen
through the prism of the COG approach and discusses the COG
Renal Tumor Committee’s blueprint to improve the outcomes of
children and adolescents with renal tumors.
STATE OF THE DISEASE - CLINICAL
Overview and Incidence
The kidney is the site of approximately 7% of childhood
malignancies, including FHWT, AHWT, clear cell sarcoma of
the kidney (CCSK), MRT, RCC, congenital mesoblastic neph-
roma and other rare tumors. Over 600 subjects per year enroll
on the COG AREN03B2 Renal Tumor Classiﬁcation, Biology,
and Banking Study, which captures the majority of pediatric
and adolescent renal tumor cases in the United States and Canada.
Wilms tumor is the most common pediatric renal tumor, but the
incidence of RCC surpasses that of Wilms tumor in adolescents
and young adults over age 15 [11].
Staging and Risk Stratification
Several clinical and biological factors contribute to the current
COG risk stratiﬁcation schema. The most important prognostic
Renal malignancies are among the most prevalent pediatric
cancers. The most common is favorable histology Wilms tumor
(FHWT), which has 5-year overall survival exceeding 90%. Other
pediatric renal malignancies, including anaplastic Wilms tumor,
clear cell sarcoma, malignant rhabdoid tumor, and renal cell carci-
noma, have less favorable outcomes. Recent clinical trials have
identiﬁed gain of chromosome 1q as a prognostic marker for
FHWT. Upcoming studies will evaluate therapy adjustments based
on this and other novel biomarkers. For high-risk renal tumors, new
treatment regimens will incorporate biological therapies. A research
blueprint, viewed from the perspective of the Children’s Oncology
Group, is presented. Pediatr Blood Cancer 2013;60:994–1000.
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marker is tumor histology. High-risk histology includes Wilms
tumor with anaplasia, CCSK, MRT, and RCC. The second most
important determinant is tumor stage. As is the case in most
tumors, low stage portends better outcome than high stage.
Stage V is a special designation for synchronous bilateral renal
tumors, which are associated with outcomes inferior to stage IV
tumors (distant metastatic disease). Other factors that contribute
to risk stratiﬁcation for FHWT include patient age, tumor weight,
loss of heterozygosity (LOH) at 1p and 16q, and completeness of
lung nodule response after 6 weeks of chemotherapy. Based on a
compilation of these factors, patients are stratiﬁed into ﬁve risk
categories for enrollment onto present COG treatment studies:
very-low risk, low-risk, standard risk, higher-risk favorable
histology, and high-risk. These categories are summarized in
Table I.
Current Outcome
The outcomes for pediatric renal tumors treated on NWTS-5
are indicated in Table II [4,6,12–14]. An interpretation of overall
outcomes for pediatric renal tumors would be incomplete without
consideration of late effects of therapy. Although certain subsets
of Wilms tumor have outstanding relapse-free (RFS) and overall
(OS) survival, 24% of survivors have severe (grade 3–4) chronic
health conditions 25 years post-diagnosis [10]. The cumulative
incidence of second malignant solid tumors in Wilms tumor sur-
vivors at age 40 years is 6.7% [15]. The cumulative incidence of
congestive heart failure is 4.4% at 20 years in patients treated with
doxorubicin [16]. Female Wilms tumor survivors who received
ﬂank radiation are at increased risk for pregnancy-related hyper-
tension, premature labor, fetal malposition and delivery of infants
with low birth weights [17]. With reductions of chemotherapy and
radiotherapy exposure compared to past treatment protocols, it is
expected that the prevalence of late effects will decrease in the
future. Nevertheless, even current regimens are predicted to have
potential for signiﬁcant late effects.
STATE OF THE DISEASE—BIOLOGICAL
Molecular Targets
Tremendous strides have been made in our understanding of
the molecular genetics of pediatric renal tumors. For Wilms
tumor, approximately 15–20% of sporadic tumors have WT1
mutations or deletions. Because the WT1 transcription factor
regulates the expression of multiple genes, there is not a clear,
currently drugable molecular target that has emerged for WT1
mutated tumors. Up to 70% of Wilms tumors have loss of im-
printing (LOI) or LOH at 11p15, leading to IGF2 overexpression
[18,19]. Moreover, IGF2 overexpression appears to be a driver of
Wilms tumorigenesis, as evidenced by increased risk of Wilms
tumor in individuals with the speciﬁc subtype of Beckwith–
Wiedemann syndrome associated with IGF2 LOI and the devel-
opment of Wilms tumors in transgenic mice overexpressing Igf2
in the setting of Wt1 ablation [20,21]. Agents targeting the IGF1R
pathway are therefore attractive therapeutic targets for Wilms
tumor. Approximately 35% of Wilms tumors have mutations in
CTNNB1 (b-catenin) or WTX, which are components of the WNT
signaling pathway [22]. Additional targets of interest, based on
tumor tissue protein expression, speciﬁc molecular interrogation,
RNA expression proﬁling, pre-clinical activity in xenograft
models, and clinical responses in phase I and II studies, include
antiangiogenic compounds, aurora-A-kinase, mTOR, c-Met,
JAK2, and telomerase inhibitors, as well as agents functioning
independent of p53 (75% of anaplastic Wilms tumors have p53
mutations). Of note, the general category of anti-mitotic drugs
demonstrates anti-Wilms efﬁcacy in xenograft models [23–25].
Malignant rhabdoid tumor is caused by deletions and muta-
tions of the SMARCB1 gene on chromosome 22q (also referred to
as INI1, BAF47, and SNF5) [26–28]. SMARCB1 encodes a mem-
ber of the SWI/SNF chromatin remodeling complex, which
regulates transcription by controlling access of transcription ma-
chinery to gene promoters [29]. The genes involved in the devel-
opment of rhabdoid tumor remain to be elucidated, but several
TABLE I. Current COG Risk Stratiﬁcation for Pediatric Renal Tumors
Patient age
Tumor
weight
Stage,
histology
LOH at both
1p and 16q
Rapid lung
nodule response
Risk
group
Treatment
study
<2 years <550 g I, FH Any N/A Very low AREN0532
<2 years 550 g I, FH None N/A Low None
2 years Any I, FH None N/A Low None
Any Any II, FH None N/A Low None
2 years Any I, FH LOH N/A Standard AREN0532
Any 550 g I, FH LOH N/A Standard AREN0532
Any Any II, FH LOH N/A Standard AREN0532
Any Any III, FH None Any Standard AREN0532
Any Any III, FH LOH Any Higher-FH AREN0533
Any Any IV, FH LOH Any Higher-FH AREN0533
Any Any IV, FH None Yes Standard AREN0533
Any Any IV, FH None No Higher-FH AREN0533
Any Any V, FH, AH Any Any Bilateral AREN0534
Any Any I-IV, AH, CCSK, RCC, MRT Any Any High AREN0321
FH, favorable histology Wilms tumor; AH, anaplastic histology Wilms tumor; CCSK, clear cell sarcoma of the kidney; RCC, renal cell
carcinoma; MRT, malignant rhabdoid tumor.
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lines of evidence indicate that these tumors have altered expres-
sion of members of the p16INK4A/CyclinD1/E2F pathway, which
regulates the cell cycle. Agents targeting the cyclin D1 pathway,
as well as epigenetic modiﬁers that affect chromatin remodeling
are of interest for rhabdoid tumor. Additional targets of interest,
based on pre-clinical activity in xenograft models and clinical
responses in phase I/II studies, include angiogenesis inhibitors
and aurora-A-kinase inhibitors.
The biology of pediatric RCC is distinct from its adult coun-
terpart. Whereas the vast majority of adult RCC have clear cell
histology associated with VHL mutations, this type of RCC is
very rare in children and adolescents. Only 1 of 120 children
with RCC enrolled on the COG AREN03B2 Renal Tumor
Biology, Classiﬁcation, and Banking Study have clear cell RCC.
The most common type of pediatric RCC is the translocation
subtype, which harbors translocations involving genes that encode
members of the microophthalmia (MiTF) family of transcription
factors. The most commonly involved gene is TFE3 on chromo-
some Xp11, which can fuse to several partners including ASPL
(17q25), PRCC (1q21), PSF (1p34), NonO (Xq12), and CLTC
(17q23) [30]. Translocation RCC continues to present through
adulthood, with recent estimates suggesting that translocation
RCC accounts for approximately 1–5% of adult renal cell carci-
noma. Biological targets of interest have now been identiﬁed and
include c-Met [31], mTOR, and VEGFR. A phase II study of the
c-MET inhibitor ARQ197 (tivantinib) in this group of cancers did
not produce objective responses in the few patients treated [32].
Reports of disease stabilization with mTOR inhibitors are avail-
able [33,34]. Anecdotal evidence of response of translocation
RCC to VEGF receptor tyrosine kinase inhibitors is growing,
with frequent objective responses and rare durable complete
remissions, predominantly with sunitinib therapy, in both pediat-
ric and adult patients [33,35–37].
Molecular Prognostic factors
Molecular markers that have been described with prognostic
implications include loss of heterozygosity (LOH) 1p and 16q,
gain at 1q, telomerase expression, and certain gene expression
proﬁles [12,38,39]. LOH at chromosomes 1p and 16q were pro-
spectively analyzed as part of the NWTS-5 trial. LOH at both 1p
and 16q was associated with decreased event-free and overall
survival for FHWT [12]. Based on this observation, current
COG studies are assessing whether augmenting therapy for
patients with stage I–IV FHWT and LOH will improve outcomes.
MAJOR RECENT FINDINGS
Renal Tumor Biology, Classification, and Banking Study
(AREN03B2)
Enrollment on this study has averaged more than 600 patients
per year; nearly all cases have had central pathology, surgery, and
radiology reviews of CT scans in real time, with a turnaround
time <7 days. It is also feasible to conduct molecular LOH
analysis with a 2-week turnaround time. The central pathology
reviews continue to detect cases of high-risk renal tumors (most
notably anaplastic histology) that are not detected by institutional
pathologists and incorrectly staged tumors, highlighting the bene-
ﬁt of central review. A review of the ﬁrst 3,000 patients enrolled
on AREN03B2 revealed that 35% of cases of diffuse anaplastic
Wilms tumor were not identiﬁed by the local pathologist. A
manuscript on the value of CT scan for detecting tumor thrombus
was published [40] and another on the predictive value of CT scan
for detecting tumor rupture is in press. Abstracts on the epidemi-
ology of pediatric RCC and surgical approach were recently
presented at national meetings and will be submitted for publica-
tion shortly.
Clinically Significant Subsets of Favorable Histology
Wilms Tumor Have Been Identified Based on
Gene Expression Patterns (AREN03B1)
Two hundred twenty-four FHWT from patients enrolled onto
NWTS-5 were evaluated for (i) global gene expression patterns,
(ii) WT1, CTNNB1, WTX mutation status, and (iii) 11p15 copy
number and methylation pattern. Five subsets were identiﬁed
showing distinct differences in pathologic and clinical features;
these ﬁndings were validated in 100 additional FHWT. The gene
expression pattern of each subset was then compared with pub-
lished gene expression proﬁles during normal renal development.
A novel subset (Subset 1) consists of epithelial FHWT in infants.
These lack WT1, CTNNB1, and WTX mutations and nephrogenic
rests and none recurred. They display a gene expression pattern of
the post-induction nephron. Three subsets (Subsets 2–4) are char-
acterized by low WT1 expression and intralobar nephrogenic rests.
TABLE II. Outcomes for Pediatric Renal Tumors on NWTS-5
Histology and stage
4-year relapse-free
survival
rate (%)
4-year overall
survival
rate (%)
Favorable histology
I (<24 months/tumor weight
<550g , nephrectomy only)a
84 98
I/II, no LOH 91 98
I/II, LOH 1p and 16q 75 91
III/IV, no LOH 83 92
III/IV, LOH 1p and 16q 66 78
V, any LOH 61 81
Diffuse anaplastic histology
I 68 79
II 83 82
III 65 67
IV 33 33
V 25 42
Clear cell sarcomaa
I 100 100
II 87 97
III 73 89
IV 40 45
Malignant rhabdoid tumor
I 50 50
II 33 33
III 33 33
IV 21 21
Renal cell carcinomab
I — 92
II — 85
III — 73
IV — 14
aOutcomes are expressed as 5-year EFS and OS. bFor renal cell
carcinoma, outcomes are expressed in terms of overall survival [8].
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These differ from one another in their frequency of WT1 and
CTNNB1 mutations, age at presentation, relapse rate, and in the
developmental timing of their development. The largest subset
(Subset 5) is characterized by biallelic methylation of the imprint
control region 1 of 11p15, and both intralobar and perilobar
nephrogenic rests. These data provide a biologic explanation for
the clinical and pathologic heterogeneity seen within WT, and
enable the future development of subset-speciﬁc therapeutic strat-
egies [41].
Genetic and Epigenetic Features May Be Used to Better
Stratify Patients Eligible for Treatment Without
Adjuvant Chemotherapy (AREN10B1)
Patients <24 months of age with Stage I FHWT weighing
<550 g are deﬁned as having very low risk WT (VLRWT) and
were treated with surgery alone on NWTS-5. The study closed
early due to a relapse rate that exceeded the pre-deﬁned stopping
rules. The overall survival rate was outstanding, but patients with
relapse were exposed to doxorubicin and radiation therapy that
they otherwise would not have received [42,43]. It would be
advantageous to identify biological prognostic factors to select
patients who do not require adjuvant therapy. Gene expression
analyses have identiﬁed subgroups of VLRWT patients with dis-
tinct prognosis. Subsets 1 and 2 (described above) each account
for 30% of VLRWT. None of the patients with Subset 1 VLRWT
treated on NWTS-5 relapsed, even when they did not receive
adjuvant chemotherapy [44]. By contrast, patients with Subset 2
VLRWT had increased risk of relapse when they were not treated
with chemotherapy, though patients with Subset 2 tumors had an
excellent outcome when they received adjuvant chemotherapy
[44].
Expanding on the above analysis, all VLRWT registered on
NWTS-5 who did not receive adjuvant chemotherapy were ana-
lyzed for LOH at 11p15 and for WT1 mutation (both of which
were features of Subset 2 tumors) and retention of imprinting
(ROI) at 11p15 (which characterizes Subset 1 tumors). In this
study, LOH, as determined by 11p15 methylation analysis, was
signiﬁcantly associated with relapse in VLRWT (P < 0.0001) as
were WT1 abnormalities (P ¼ 0.004) [45]. If these results are
validated in an independent cohort of patients, it would be worth-
while to conduct a clinical trial that uses molecular genetic factors
rather than the arbitrarily deﬁned clinical factors of patient age
and tumor weight to identify patients with stage I FHWT who do
not require adjuvant therapy. It is anticipated that such a trial
would expand the number of patients who would be candidates
to be treated with surgery only.
Chromosome 1q Gain May Serve as a New Prognostic
Marker for FHWT (AREN11B3)
A number of large studies using convenience samples consis-
tently showed a frequency of 1q gain in FHWT of 25% and a
strong association between 1q gain and relapse, with relative risks
of 2.5, 2.75, and 3.14 [46–49]. These studies were based on
cytogenetic, classic CGH, array-CGH, and gene expression anal-
yses. The combination of high prevalence and high relative risk
indicates a potentially strong biomarker for relapse. The immedi-
ate clinical impact of analysis of 1q gain (assuming a conservative
projected relative risk of at least 2.0 and a prevalence of 25%) is
the accurate prediction of at least 40% of relapses, compared with
the current ability to detect 9% of relapses using LOH at chromo-
some 1p and 16q. To assess the prognostic signiﬁcance of 1q gain
in a uniformly treated group of patients, 226 evaluable samples
from NWTS-4 were assessed for 1q gain using multiplex ligation-
dependent probe ampliﬁcation (MLPA). Consistent with previous
studies, 25% of samples demonstrated 1q gain. The 8-year RFS
was 76% (95% CI 63%, 85%) for those with 1q gain and 93%
(95% CI 87%, 96%) for those who lacked 1q gain (P ¼ 0.0024).
The 8-year OS was 89% (95% CI 78%, 95%) for those with 1q
gain, and 98% (95% CI 94%, 99%) for those who lacked 1q gain
(P ¼ 0.0075). There were too few events to analyze the effect of
1q gain within stage subsets. However, there was no indication
that 1q gain correlated with disease stage (Gratias, manuscript in
preparation). Conﬁrmatory analysis of 1,700 NWTS-5 samples is
in progress and will enable multi-variate analysis that takes into
account other clinical and biological risk factors. If the prognostic
signiﬁcance of 1q gain is conﬁrmed, future clinical trials could
incorporate 1q gain into a new risk stratiﬁcation schema for FHWT.
STRATEGIC APPROACH
Newly Diagnosed Population
To prioritize research initiatives, renal tumors may be classi-
ﬁed by RFS and the potential for acute and long-term treatment-
related adverse effects (Table III). Four main categories of
patients are deﬁned:
Excellent RFS and low potential for late effects: Given the num-
ber of patients available for study, it is unlikely that outcomes can
be measurably improved using classic clinical trial designs. Most
patients in this category are enrolled on the biology and classiﬁ-
cation study (AREN03B2), but are not treated on a therapeutic
study. Subsets of patients will have compelling biomarkers that
suggest that a change in therapy may be justiﬁed. For example,
ROI at chromosome 11p15 may identify patients who do not
require adjuvant therapy at all, as described in the Major Recent
Findings Section. In addition, application of 1q gain ﬁndings may
identify apparently low risk patients that should be considered for
augmented therapy.
Excellent RFS and moderate-high potential for late effects: For
these patients, there is opportunity to pursue a reduction in thera-
py. If 1q gain is validated as a prognostic factor, a new primary
aim may be to eliminate doxorubicin from patients with stage III
FHWT without 1q gain.
Good RFS and moderate to high potential for late effects: Here,
there is opportunity to improve tumor control and decrease thera-
py-related toxicity. The plan for this category of patients involves
therapeutic studies that either augment or reduce therapy, depend-
ing on the strength of the scientiﬁc rationale for a change in
treatment.
Unsatisfactory RFS: With RFS <75%, the priority is to develop
novel treatment regimens and targeted therapy based on biologi-
cal studies and pre-clinical testing.
Relapsed Wilms Tumor
Patients with relapsed Wilms tumor may be divided into three
risk groups (standard, high, and very high) according to overall
survival rates after salvage therapy [50]. The standard risk group
COG 2013 Blueprint: Renal Tumors 997
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includes patients with non-anaplastic Wilms tumor with relapse
after therapy with only vincristine and/or dactinomycin. These
patients are expected to have survival rates in the 70–80% range
[51]. The high-risk group includes patients with non-anaplastic
Wilms tumor with relapse after therapy with three or more agents,
typically vincristine, dactinomycin, doxorubicin, and cyclophos-
phamide. These patients are expected to have survival rates in the
40–50% range [2]. The very high-risk group includes patients
with recurrent anaplastic or blastemal-type WT. These patients
are expected to have survival rates in the 10% range [4,52].
Improved outcomes for the high-risk and very-high risk groups
will likely require novel treatment regimens that combine stan-
dard chemotherapy with molecularly targeted agents.
KEY TRIALS TO BE PURSUED BY COG
Front-Line Study for Favorable Histology Wilms Tumor
A single, multi-strata clinical trial is planned for patients with
FHWT. The centerpiece of the trial is a new risk stratiﬁcation
system that uses ROI at 11p15 and gain of chromosome 1q as
biomarkers. The plans outlined below are contingent upon suc-
cessful validation of these prognostic markers using independent
patient cohorts.
The ﬁrst stratum will include patients with stage I FHWT. The
aim will be to determine whether patients whose tumors have ROI
at 11p15 will have outstanding overall survival without adjuvant
chemotherapy. The rationale for this study is based on the results
outlined above for the AREN10B1 study. Among NWTS-5
patients treated with nephrectomy only, there were no relapses
in patients with retention of heterozygosity at 11p15 and without
WT1 mutation. Conversely, loss of imprinting at 11p15 was as-
sociated with relapse.
The second stratum will include patients with stage III FHWT
without gain of chromosome 1q and without LOH at 1p and 16q.
The objective will be to determine whether doxorubicin can be
eliminated from front-line therapy for such patients. Long-term
follow-up data on NWTS-3 and -4 indicate that doxorubicin
contributes to relapse-free survival, but not overall survival
[53,54]. Moreover, the SIOP-2001 randomized patients with stage
II and III disease with intermediate-risk histology to receive or not
receive doxorubicin. The results showed no difference in overall
survival with or without doxorubicin [55]. Based on these
ﬁndings, we propose to evaluate whether excellent RFS and OS
can be preserved when doxorubicin is omitted from the treatment
of patients without 1q gain, estimated to be 75% of the stage III
population.
The third stratum will include patients with FHWT and gain of
chromosome 1q, with the objective of assessing whether augmen-
tation of therapy improves RFS. For patients with stage I/II
FHWT, doxorubicin will be added to vincristine and dactinomy-
cin therapy. For patients with stage III/IV FHWT, cyclophospha-
mide and etoposide will be added to vincristine, dactinomycin,
and doxorubicin. As outlined in the Recent Findings Section
above, the rationale for augmenting therapy is that previous stud-
ies have found that 1q gain is observed in 25% of Wilms tumor
samples and is associated with a RR of recurrence of approxi-
mately 2.5–3.
An additional objective for patients with stage IV disease will
be to determine the feasibility of intensity modulated radiation
therapy (IMRT) in children receiving whole lung and liver irradi-
ation. The goal would be to reduce the amount of radiation
delivered to the heart, liver, and possibly the thyroid gland. To
limit XRT exposure, the AREN0533 study is withholding lung
XRT for patients with stage IV FHWT whose lung nodules re-
solve by week 6 of treatment. So far on AREN0533, approxi-
mately 40% of patients are not receiving XRT. To reduce XRT
exposure in the patients who do not have a rapid response, COG
plans to study the feasibility of IMRT. The use of IMRT in
conjunction with respiratory gating techniques has enabled the
safer delivery of higher doses of RT to the thoracic structures
such as lung and pleura in adult patients with lung cancer and
mesothelioma, respectively [56,57]. The implementation, compli-
ance, and efﬁcacy of whole lung IMRT will have to be evaluated
carefully before it can be considered as a standard alternative to
conventional whole lung irradiation in children with Wilms tumor.
Therapy for Bilateral Wilms Tumor (BWT)
BWT presents the dual challenge of maintaining tumor control
and preserving nephrons. The 8-year EFS for BWTwas only 74%
among patients enrolled on NWTS-4 [13]. Moreover, the cumu-
lative rate of end-stage renal disease in long-term survivors of
BWT without syndromic features was 12% [58]. The COG
AREN0534 study is attempting to decrease the rate of recurrence
TABLE III. Pediatric Renal Tumors by RFS and Potential for Late Effects
Relapse-free survival (NWTS-5)
Potential for late effects
Low Moderate to high
Excellent (85%) Stage I/II FHWT, LOH (210 patients per year) Stage I/II CCSK
Stage III FHWT, LOH (125 patients per year)
Good (75–84%) Stage IV FHWT, LOH
Stage II AHWT
Stage III CCSK (70 patients per year)
Unsatisfactory (<75%) Stage I/II FHWT, LOHþ Stage III/IV FHWT, LOHþ
Stage I AHWT Stage III/IVAHWT
Stage III/IV RCC (35 patients per year) Stage V WT
Stage IV CCSK
Stage I–IV MRT
Relapsed FHWT (125 patients per year)
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and enhance nephron sparing surgery by treating all patients with
doxorubicin in addition to vincristine and dactinomycin for the
ﬁrst 6–12 weeks of therapy. Nephron-sparing surgery is mandated
by week 12 and post-surgical therapy is tailored according to
histology using the SIOP post-chemotherapy histologic risk clas-
siﬁcation schema. This study is expected to continue until 2015.
Therapy for Relapsed FHWT and Other High-Risk
Renal Tumors
The NWTS-5 protocol for high-risk recurrent FHWT used
cyclophosphamide/etoposide alternating with carboplatin/etopo-
side. The 4-year RFS and OS were only 42% and 48%, respec-
tively [2]. A novel randomized phase 2 study design using a
decision analysis approach [59–61] will be conducted to evaluate
the contribution of a biological agent to a chemotherapy backbone
that incorporates topotecan, recently shown to be active in recur-
rent Wilms tumor [62], in addition to other active agents (ifosfa-
mide, carboplatin, etoposide, and cyclophosphamide) The
selection of the biological agent will depend on results of ongoing
COG phase 1 and 2 studies of agents targeting IGF1R, aurora A
kinase, c-MET, JAK2, and the multi-targeted/VEGF receptor ki-
nase inhibitors. A similar approach to incorporate molecularly
targeted therapy is envisioned for frontline therapeutic trials for
diffuse anaplastic Wilms tumor and malignant rhabdoid tumor.
Therapy for Translocation RCC
COG is planning a prospective therapeutic study of transloca-
tion RCC, a renal tumor that affects primarily adolescents and
young adults. The study would be conducted in collaboration with
the Eastern Cooperative Oncology Group (ECOG) and other adult
cooperative groups. Based on preliminary data from retrospective
studies that sunitinib has activity against translocation RCC
[33,35–37], the efﬁcacy of sunitinib or newer generation multi-
tyrosine kinase inhibitors will be studied prospectively. The fea-
sibility of conducting a Phase 2 study in this rare disease through
inter-group cooperation will be determined, the clinical descrip-
tion of translocation RCC will be reﬁned, and the surgical and
radiological guidelines and practices will be characterized.
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